AU2007232297B2 - Amide substituted indazole and benzotriazole derivatives as poly(ADP-ribose)polymerase (PARP) inhibitors - Google Patents

Amide substituted indazole and benzotriazole derivatives as poly(ADP-ribose)polymerase (PARP) inhibitors Download PDF

Info

Publication number
AU2007232297B2
AU2007232297B2 AU2007232297A AU2007232297A AU2007232297B2 AU 2007232297 B2 AU2007232297 B2 AU 2007232297B2 AU 2007232297 A AU2007232297 A AU 2007232297A AU 2007232297 A AU2007232297 A AU 2007232297A AU 2007232297 B2 AU2007232297 B2 AU 2007232297B2
Authority
AU
Australia
Prior art keywords
alkyl
indazol
aminocarbonyl
compound
trifluoroacetate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active, expires
Application number
AU2007232297A
Other languages
English (en)
Other versions
AU2007232297A1 (en
Inventor
Julia Kay Boueres
Danila Branca
Federica Ferrigno
Philip Jones
Ester Muraglia
Jesus Maria Ontoria Ontoria
Federica Orvieto
Rita Scarpelli
Carsten Schultz-Fademrecht
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MSD Italia SRL
Original Assignee
MSD Italia SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0606663A external-priority patent/GB0606663D0/en
Priority claimed from GB0615907A external-priority patent/GB0615907D0/en
Priority claimed from GBGB0700432.8A external-priority patent/GB0700432D0/en
Application filed by MSD Italia SRL filed Critical MSD Italia SRL
Publication of AU2007232297A1 publication Critical patent/AU2007232297A1/en
Application granted granted Critical
Publication of AU2007232297B2 publication Critical patent/AU2007232297B2/en
Assigned to MSD ITALIA S.R.L. reassignment MSD ITALIA S.R.L. Request for Assignment Assignors: ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA
Active legal-status Critical Current
Adjusted expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/16—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C07D249/18—Benzotriazoles
    • C07D249/20—Benzotriazoles with aryl radicals directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AU2007232297A 2006-04-03 2007-04-02 Amide substituted indazole and benzotriazole derivatives as poly(ADP-ribose)polymerase (PARP) inhibitors Active 2032-04-02 AU2007232297B2 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GB0606663.3 2006-04-03
GB0606663A GB0606663D0 (en) 2006-04-03 2006-04-03 Therapeutic compounds
GB0615907.3 2006-08-11
GB0615907A GB0615907D0 (en) 2006-08-11 2006-08-11 Therapeutic Compounds
GBGB0700432.8A GB0700432D0 (en) 2007-01-10 2007-01-10 Therapeutic compounds
GB0700432.8 2007-01-10
PCT/GB2007/050177 WO2007113596A1 (en) 2006-04-03 2007-04-02 Amide substituted indazole and benzotriazole derivatives as poly(adp-ribose)polymerase (parp) inhibitors

Publications (2)

Publication Number Publication Date
AU2007232297A1 AU2007232297A1 (en) 2007-10-11
AU2007232297B2 true AU2007232297B2 (en) 2012-09-20

Family

ID=38441875

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2007232297A Active 2032-04-02 AU2007232297B2 (en) 2006-04-03 2007-04-02 Amide substituted indazole and benzotriazole derivatives as poly(ADP-ribose)polymerase (PARP) inhibitors

Country Status (6)

Country Link
US (2) US20090275619A1 (https=)
EP (1) EP2007733B1 (https=)
JP (1) JP4611441B2 (https=)
AU (1) AU2007232297B2 (https=)
CA (1) CA2647545C (https=)
WO (1) WO2007113596A1 (https=)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0610680D0 (en) * 2006-05-31 2006-07-12 Istituto Di Ricerche D Biolog Therapeutic compounds
JP4611444B2 (ja) * 2007-01-10 2011-01-12 イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー ポリ（ａｄｐ−リボース）ポリメラーゼ（ｐａｒｐ）阻害剤としてのアミド置換インダゾール
CN101778838A (zh) * 2007-05-24 2010-07-14 惠氏有限责任公司 作为组胺-3拮抗剂的氮杂环基苯甲酰胺衍生物
US7732491B2 (en) * 2007-11-12 2010-06-08 Bipar Sciences, Inc. Treatment of breast cancer with a PARP inhibitor alone or in combination with anti-tumor agents
KR101653548B1 (ko) * 2008-01-08 2016-09-02 머크 샤프 앤드 돔 리미티드 2-｛4-［（3ｓ）-피페리딘-3-일］페닐｝-2ｈ-인다졸-7-카복스아미드의 약제학적으로 허용되는 염
WO2009099736A2 (en) * 2008-02-06 2009-08-13 Lead Therapeutics, Inc. Benzoxazole carboxamide inhibitors of poly(adp-ribose)polymerase (parp)
GB0804755D0 (en) 2008-03-14 2008-04-16 Angeletti P Ist Richerche Bio Therapeutic compounds
ITFI20090005A1 (it) * 2009-01-19 2010-07-20 Alberto Chiarugi Formulazioni farmaceutiche per indurre immunosoppressione attraverso l'inibizione del fenomeno dell'epitope spreading e loro uso.
JP5852958B2 (ja) * 2009-07-14 2016-02-03 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ Ｐａｒｐ阻害剤としての３−オキソ−２，３−ジヒドロ−１ｈ−イソインドール−４−カルボキサミド
JP5744019B2 (ja) * 2009-07-14 2015-07-01 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ 選択的ｐａｒｐ−１阻害を有する３−オキソ−２，３−ジヒドロ−１ｈ−イソインドール−４−カルボキサミド
WO2011123795A1 (en) 2010-04-02 2011-10-06 Battelle Memorial Institute Methods for associating or dissociating guest materials with a metal organic framework, systems for associating or dissociating guest materials within a series of metal organic frameworks, and gas separation assemblies
AU2011251622A1 (en) 2010-05-10 2012-12-20 Radikal Therapeutics Inc. Lipoic acid and nitroxide derivatives and uses thereof
CN103052633B (zh) * 2010-07-14 2016-03-23 贝达药业股份有限公司 酰胺基取代的吲唑衍生物类聚(adp-核糖)聚合酶抑制剂
WO2012006958A1 (en) * 2010-07-14 2012-01-19 Zhejiang Beta Pharma Inc. Amids substituted indazole derivativees as ploy(adp-ribose)polymerase inhibitors
JP5951625B2 (ja) 2010-11-24 2016-07-13 ザ・トラスティーズ・オブ・コランビア・ユニバーシティー・イン・ザ・シティー・オブ・ニューヨークＴｈｅ Ｔｒｕｓｔｅｅｓ Ｏｆ Ｃｏｌｕｍｂｉａ Ｕｎｉｖｅｒｓｉｔｙ Ｉｎ Ｔｈｅ Ｃｉｔｙ Ｏｆ Ｎｅｗ Ｙｏｒｋ 加齢性黄斑変性症およびシュタルガルト病の処置のための非レチノイドｒｂｐ４アンタゴニスト
JP5902299B2 (ja) * 2011-07-26 2016-04-13 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ Ｐａｒｐ−１阻害剤としての３−オキソ−２，３−ジヒドロ−１ｈ−インダゾール−４−カルボキサミド誘導体
JP5468119B2 (ja) 2011-09-26 2014-04-09 日東電工株式会社 増強された太陽光集光効率のための高蛍光性かつ光安定性の発色団
TW201317327A (zh) 2011-10-05 2013-05-01 Nitto Denko Corp 波長轉換膜、其形成方法以及其使用方法
TW201331192A (zh) * 2012-01-17 2013-08-01 Zhejiang Beta Pharma Inc 醯胺基取代的吲唑衍生物類聚（ａｄｐ－核糖）聚合酶抑制劑
US9333202B2 (en) 2012-05-01 2016-05-10 The Trustees Of Columbia University In The City Of New York Non-retinoid antagonists for treatment of age-related macular degeneration and stargardt disease
EP2928473B1 (en) * 2012-12-07 2017-06-28 Merck Sharp & Dohme Corp. Regioselective n-2 arylation of indazoles
US9944644B2 (en) 2013-03-14 2018-04-17 The Trustees Of Columbia University In The City Of New York Octahydropyrrolopyrroles their preparation and use
US9938291B2 (en) 2013-03-14 2018-04-10 The Trustess Of Columbia University In The City Of New York N-alkyl-2-phenoxyethanamines, their preparation and use
EP3495357B1 (en) 2013-03-14 2021-05-05 The Trustees of Columbia University in the City of New York 4-phenylpiperidines, their preparation and use
WO2014152018A1 (en) * 2013-03-14 2014-09-25 The Trustees Of Columbia University In The City Of New York Octahydrocyclopentapyrroles, their preparation and use
WO2014210255A1 (en) 2013-06-26 2014-12-31 Abbvie Inc. Primary carboxamides as btk inhibitors
US10989719B2 (en) * 2013-10-11 2021-04-27 National University Corporation Tokyo Medical And Dental University Methods for treating spinocerebellar ataxia type I using RPA1
SG11201608943VA (en) 2014-04-30 2016-11-29 Univ Columbia Substituted 4-phenylpiperidines, their preparaiton and use
WO2016203405A1 (en) * 2015-06-19 2016-12-22 Novartis Ag Compounds and compositions for inhibiting the activity of shp2
AU2016296905B2 (en) 2015-07-23 2018-07-05 Centre National De La Recherche Scientifique Use of a combination of Dbait molecule and parp inhibitors to treat cancer
WO2017134066A1 (en) 2016-02-05 2017-08-10 Syngenta Participations Ag Pesticidally active heterocyclic derivatives with sulphur containing substituents
SG11201811564QA (en) 2016-06-29 2019-01-30 Tesaro Inc Methods of treating ovarian cancer
UA124972C2 (uk) 2016-07-29 2021-12-22 Янссен Фармацевтика Нв Способи лікування раку передміхурової залози
WO2018162439A1 (en) 2017-03-08 2018-09-13 Onxeo New predictive biomarker for the sensitivity to a treatment of cancer with a dbait molecule
CN110944638A (zh) 2017-03-27 2020-03-31 特沙诺有限公司 尼拉帕尼组合物
EP3606524B1 (en) * 2017-04-04 2021-12-01 Combiphos Catalysts, Inc. Deuterated (s)-2-(4-(piperidin-3-yl)phenyl)-2h-indazole-7-carboxamide
MA48475A (fr) 2017-04-24 2020-03-04 Tesaro Inc Procédés de fabrication de niraparib
TW202444417A (zh) 2017-05-09 2024-11-16 美商提薩羅有限公司 治療癌症的組合療法
KR102014478B1 (ko) * 2017-05-12 2019-08-26 한국화학연구원 신규한 피페리딘-2,6-디온 유도체 및 이의 용도
WO2018208123A1 (ko) * 2017-05-12 2018-11-15 한국화학연구원 신규한 피페리딘-2,6-디온 유도체 및 이의 용도
KR20200005662A (ko) 2017-05-18 2020-01-15 테사로, 인코포레이티드 암을 치료하기 위한 조합 요법
HUE062956T2 (hu) 2017-08-14 2023-12-28 Teva Pharmaceuticals Int Gmbh Eljárások niraparib és köztitermékei elõállítására
TWI843707B (zh) 2017-09-26 2024-06-01 美商提薩羅有限公司 尼拉帕尼（ｎｉｒａｐａｒｉｂ）調配物
MX2020003770A (es) 2017-09-30 2020-07-29 Tesaro Inc Terapias de combinacion para tratar cancer.
EA202090655A1 (ru) 2017-10-06 2020-12-07 Тесаро, Инк. Комбинированные терапевтические средства и их применение
CN111918667A (zh) 2018-02-05 2020-11-10 特沙诺有限公司 儿科尼拉帕尼配制剂和儿科治疗方法
CA3092779A1 (en) 2018-03-13 2019-09-19 Onxeo A dbait molecule against acquired resistance in the treatment of cancer
BR112020018832A2 (pt) 2018-03-29 2021-02-09 Elex Biotech, Inc. compostos para o tratamento de arritimias cardíacas e insuficiência cardíaca
WO2019200382A1 (en) * 2018-04-13 2019-10-17 The Board Of Regents Of University Of Texas System Nanoparticle compositions and methods of use of parp inhibitor for treatment of cancer
JP2022504228A (ja) 2018-10-03 2022-01-13 テサロ， インコーポレイテッド ニラパリブ遊離塩基の結晶形態
KR102735378B1 (ko) * 2018-11-09 2024-11-27 한국화학연구원 신규한 피페리딘-2,6-디온 유도체 및 이의 용도
US20230002361A1 (en) * 2019-06-27 2023-01-05 Biogen Ma Inc. 2h-indazole derivatives and their use in the treatment of disease
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
CA3169303A1 (en) * 2020-02-24 2021-09-02 Xiaokun SHEN Application of poly adp-ribose polymerase inhibitors in corona virus resistance
CN121398822A (zh) 2023-06-21 2026-01-23 四方生物科学有限公司 用于在治疗hr功能正常的癌症的方法中的用途的包含脱氧胞苷衍生物和parp抑制剂的组合

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003005323A (ja) * 2001-06-20 2003-01-08 Konica Corp 熱現像写真感光材料及び画像形成方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0841924B1 (en) * 1995-08-02 2002-10-02 Newcastle University Ventures Limited Benzimidazole compounds
IL142917A0 (en) * 1998-11-03 2002-04-21 Basf Ag Substituted 2-phenylbenzimidazoles, the production thereof and their use
HRP20010451A2 (en) * 1998-11-17 2003-04-30 Basf Ag 2-phenylbenzimidazoles and 2-phenylindoles, and production and use thereof
TR200101498T2 (tr) * 1998-11-27 2001-11-21 Basf Aktiengesellschaft İkameli benzimidazoller ve parp inhibitörleri olarak kullanımları
DE19918211A1 (de) * 1999-04-22 2000-10-26 Basf Ag Cycloalkylsubstituierte Benzimidazole, deren Herstellung und Anwendung
DE19920936A1 (de) * 1999-05-07 2000-11-09 Basf Ag Heterozyklisch substituierte Benzimidazole, deren Herstellung und Anwendung
DE50112961D1 (de) * 2000-02-01 2007-10-18 Abbott Gmbh & Co Kg Heterozyklische verbindungen und deren anwendung als parp-inhibitoren
DE10022925A1 (de) * 2000-05-11 2001-11-15 Basf Ag Substituierte Indole als PARP-Inhibitoren
AU2003296405A1 (en) * 2003-01-06 2004-08-10 Eli Lilly And Company Fused heterocyclic derivatives as ppar modulators
WO2005066136A1 (en) * 2003-12-22 2005-07-21 Eli Lilly And Company Bicyclic derivatives as ppar modulators
PT1794163E (pt) * 2004-09-22 2010-03-01 Pfizer Método para a preparação de inibidores de poli(adpribose)- polimerases
US7728026B2 (en) * 2005-04-11 2010-06-01 Abbott Laboratories, Inc. 2-substituted-1 h-benzimidazile-4-carboxamides are PARP inhibitors
TWI375673B (en) * 2005-04-11 2012-11-01 Abbott Lab 1h-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent parp inhibitors
JP5227796B2 (ja) * 2005-09-29 2013-07-03 アボット・ラボラトリーズ ２位においてフェニルによって置換された１ｈ−ベンズイミダゾール−４−カルボキサミドは強力なｐａｒｐ阻害薬である
JP5162465B2 (ja) * 2005-11-15 2013-03-13 アボット・ラボラトリーズ 置換１ｈ−ベンズイミダゾール−４−カルボキサミド類は強力なｐａｒｐ阻害薬である
MX2008014004A (es) * 2006-05-02 2008-11-12 Abbott Lab 1h-benzimidazol-4-carboxamidas sustituidas son inhibidores de parp potentes.
JP4611444B2 (ja) * 2007-01-10 2011-01-12 イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー ポリ（ａｄｐ−リボース）ポリメラーゼ（ｐａｒｐ）阻害剤としてのアミド置換インダゾール

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003005323A (ja) * 2001-06-20 2003-01-08 Konica Corp 熱現像写真感光材料及び画像形成方法

Also Published As

Publication number Publication date
US20110201657A1 (en) 2011-08-18
CA2647545C (en) 2016-02-23
JP4611441B2 (ja) 2011-01-12
EP2007733A1 (en) 2008-12-31
EP2007733B1 (en) 2016-05-25
CA2647545A1 (en) 2007-10-11
JP2009532452A (ja) 2009-09-10
AU2007232297A1 (en) 2007-10-11
WO2007113596A1 (en) 2007-10-11
US20090275619A1 (en) 2009-11-05

Similar Documents

Publication Publication Date Title
AU2007232297B2 (en) Amide substituted indazole and benzotriazole derivatives as poly(ADP-ribose)polymerase (PARP) inhibitors
CN101415686B (zh) 作为聚(adp-核糖)聚合酶(parp)抑制剂的酰胺取代的吲唑和苯并三唑衍生物
EP2029551B1 (en) Pyridinone and pyridazinone derivatives as inhibitors of poly(adp-ribose)polymerase (parp)
US7834015B2 (en) Pyrrolo[1,2-a] pyrazin-1(2H)-one and pyrrolo[1,2-d][1,2,4]triazin-1(2H)-one derivatives as inhibitors of poly(ADP-ribose)polymerase (PARP)
US8362030B2 (en) Tricyclic derivatives as inhibitors of poly(ADP-ribose) polymerase (PARP)
US20100152180A1 (en) 4-oxo-4,5-dihydropyrrolo[1,2-A)quinoxaline derivatives as inhibitors of poly(ADP-ribose) polymerase (PARP)
WO2008001134A1 (en) 1,2,3,8,9,9a-hexahydro-7h-benzo(de)-1,7-naphthyridin-7-one derivatives as inhibitors of poly(adp-ribose) polymerase (parp)
US20100173895A1 (en) Imidazolopyrimidines and imidazolotriazine derivatives as inhibitors of poly(adp-ribose)polymerase(parp)
WO2012006958A1 (en) Amids substituted indazole derivativees as ploy(adp-ribose)polymerase inhibitors
WO2008041037A1 (en) Fused indoles and indazoles as inhibitors of poly(adp-ribose)polymerase (parp)

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: MSD ITALIA S.R.L.

Free format text: FORMER OWNER WAS: ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA

NC Extension of term for standard patent requested (sect. 70)

Free format text: PRODUCT NAME: ZEJULA NIRAPARIB

Filing date: 20190628

NDA Extension of term for standard patent accepted (sect.70)

Free format text: PRODUCT NAME: ZEJULA NIRAPARIB

Filing date: 20190628

NDB Extension of term for standard patent granted (sect.76)

Free format text: PRODUCT NAME: ZEJULA NIRAPARIB

Filing date: 20190628

Extension date: 20320402